Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce a milestone for its novel blood test for endometriosis, PromarkerEndo, with the clinical validation of the biomarker panel in an independent patient group.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce a milestone for its novel blood test for oesophageal adenocarcinoma, PromarkerEso, with the clinical validation of the biomarker panel in a second independent patient group.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce that it has received firm commitments from new and existing institutional investors for a non-underwritten placement of 8.6 million new fully paid ordinary shares.
Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 31 December 2023 and subsequent to the period end.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has received human ethics approval from the Human Research Ethics Committee of The Peter MacCallum Cancer Centre for its Phase II clinical study in Pancreatic Cancer.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce the signing of a licence agreement to expand PromarkerD's reach in Central and South America.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the Chairman's Address provided by Mr Neville Gardiner and the Investor Presentation provided by Dr Richard Lipscombe to shareholders.
